DarioHealth Corp.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

DRIO$2.39+16.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited)


· · Three months ended · · Six months ended
· · June 30, · · June 30,
· · 2026 · · 2025 · · 2026 · · 2025
Revenues:
Services	$2,585	$3,661	$5,410	$8,536
Consumer hardware	2,592	1,708	5,350	3,585
Total revenues	5,177	5,369	10,760	12,121

Cost of revenues:
Services	440	821	1,002	1,686
Consumer hardware	1,367	1,151	3,010	2,281
Amortization of acquired intangible assets	178	433	354	1,308
Total cost of revenues	1,985	2,405	4,366	5,275

Gross profit	3,192	2,964	6,394	6,846

Operating expenses:
Research and development	$2,100	$3,721	$4,485	$7,829
Sales and marketing	4,971	5,231	9,870	11,104
General and administrative	2,600	3,212	5,826	6,522

Total operating expenses	9,671	12,164	20,181	25,455

Operating loss	6,479	9,200	13,787	18,609

Interest expenses	1,123	—	2,273	—
Other financial expenses (income), net	(6)	3,790	(271)	3,586

Total financial expenses, net	1,117	3,790	2,002	3,586

Loss before taxes	7,596	12,990	15,789	22,195

Income tax	328	—	384	22

Net loss	$7,924	$12,990	$16,173	$22,217

Deemed dividend	$—	$5,572	$—	$10,411

Net loss attributable to common shareholders	$7,924	$18,562	$16,173	$32,628

Net loss per share:

Basic and diluted loss per share of common stock	$0.85	$3.54	$1.75	$6.50
Weighted average number of common stock used in computing basic and diluted net loss per share**	9,343,618	2,481,548	9,238,133	2,425,039

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.